Optimer Pharmaceuticals Inc

Premium Company Profile

Publication Date	April 2008
Publisher	Datamonitor
Product Type	Report
Pages	40
ISBN Number	not applicable
Product Code	DAT11476

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

Optimer is a biopharmaceutical company focused on the discovery, development and global commercialization of anti-infective products for the treatment of serious infectious diseases. The Company currently has two late stage anti-infective product candidates, OPT-80 (Difimicin) and Prulifloxacin, at Phase III trials.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Optimer in-licensed Difimicin from Par Pharmaceuticals and Prulifloxacin from Nippon Shinyaku. In addition, the company has acquired OPopS technology from The Scripps Research Institute. Utilizing the OPopS technology the company is developing Difimicin and other internal products. Optimer recognized its historical revenues from 2004. During 2004-2006, total revenue growth was nearly constant derived from sole revenue stream, license fees, collaboration and others. The significant decline in revenues from $2 in 2005 to $1 million in 2006 was due to the lowered Small Business Innovation Research Program (SBIR) grants. Optimer's total revenues during 2006-2010 are forecasted with an absolute growth of +$97 million with sales increasing from $1 million to $98 million grows at a CAGR of 21%. The increase was primarily due to the forecasted revenues from Difimicin and Prulifloxacin.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content

Overview
Catalyst
Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- P&l
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- Ac Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Product Discovery and Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
- Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table of Figures
- Figure 1: Optimer Pharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Optimer Pharmaceuticals- Key Strategic Revenues, 2006-2010 ($ Mn)
- Tables
- Table 1: Optimer Pharmaceuticals- Key Facts
- Table 2: Optimer Pharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 3: Optimer Pharmaceuticals- Operating Cost Ratio Analysis, 2002-2006 (% of Total Revenues)
- Table 4: Optimer Pharmaceuticals- Balance Sheet
- Table 5: Optimer Pharmaceuticals- Cash Flow
- Table 6: Optimer Pharmaceuticals - in-House Pipeline Products
- Table 7: Optimer Pharmaceuticals- Collaboration Products
- Table 8: Optimer Pharmaceuticals- Forecast Sales, 2006-2010 ($ Mn)
- Table 9: Optimer Pharmaceuticals - Key Competitors
- Table 10: Optimer Pharmaceuticals- Key Suppliers
- Table 11: Optimer Pharmaceuticals- Key Clients
- Table 12: Optimer Pharmaceuticals- Key Shareholders
- Table 13: Optimer Pharmaceuticals- SWOT Analysis Summary
- Table 14: Optimer Pharmaceuticals- Value Chain Analysis
- Table 15: Optimer Pharmaceuticals- Scorecard
- Table 16: Optimer Pharmaceuticals- Key Employees
- Table 17: Optimer Pharmaceuticals - Financial and Operational Overview